Inflammatory signaling proteins and mediators

Inflammatory signaling proteins and mediators encompass a broad and heterogeneous group of molecules that orchestrate the body's response to tissue injury, pathogens, and environmental stressors. This category includes secreted signaling proteins such as cytokines (e.g., tumor necrosis factor-alpha, interleukins) and chemokines, as well as lipid-derived mediators like prostaglandins and leukotrienes (StatPearls, 2023). These molecules function by binding to specific cell-surface receptors, initiating intracellular signaling cascades—often involving Janus kinases (JAKs) or the NF-kappaB pathway—to alter gene expression and immune cell behavior (NIH, 2022). While acute inflammation is a protective mechanism, the chronic dysregulation of these mediators is a central driver in the pathogenesis of autoimmune disorders, cardiovascular diseases, and certain cancers (PubMed, 2021). Consequently, many of the most successful modern therapeutics, including monoclonal antibodies and small-molecule inhibitors, are designed to neutralize specific inflammatory mediators or block their downstream signaling. Because this term refers to a functional class rather than a single molecular entity, it represents a collection of distinct therapeutic targets rather than a specific receptor or enzyme.

Other names

Pro-inflammatory mediatorsInflammatory cytokinesInflammatory signaling moleculesInflammatory cascade components

Inhibition of pro-inflammatory cytokine activity, antagonism of inflammatory receptors, or modulation of intracellular signaling pathways (e.g., JAK/STAT, NF-kappaB) to reduce the production and effect of inflammatory mediators (PubMed, 2021).